Ryan Widau to Risk Assessment
This is a "connection" page, showing publications Ryan Widau has written about Risk Assessment.
Connection Strength
0.022
-
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017 Nov 18; 390(10109):2266-2277.
Score: 0.022